NGL FINECHEM
Back to Balance Sheet
|
NGL FINECHEM Last 5 Year Contingent Liabilities History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Contingent Liabilities | ₹0.80 Cr | ₹0.80 Cr | ₹0.44 Cr | ₹0.10 Cr | ₹0.28 Cr |
What is the latest Contingent Liabilities ratio of NGL FINECHEM ?
| Year | Contingent Liabilities |
|---|---|
| Mar2026 | ₹0.80 Cr |
| Mar2025 | ₹0.80 Cr |
| Mar2024 | ₹0.44 Cr |
| Mar2023 | ₹0.10 Cr |
| Mar2022 | ₹0.28 Cr |
How is Contingent Liabilities of NGL FINECHEM Trending?
| Years | Contingent Liabilities | % Change | |
|---|---|---|---|
| Mar2026 | ₹0.80 Cr | 0.00 | |
| Mar2025 | ₹0.80 Cr | 80.95 | |
| Mar2024 | ₹0.44 Cr | 336.63 | |
| Mar2023 | ₹0.10 Cr | -63.67 | |
| Mar2022 | ₹0.28 Cr | - | |
Compare Contingent Liabilities of peers of NGL FINECHEM
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| NGL FINECHEM | ₹1,642.5 Cr | -5.6% | -18.9% | 99.8% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹469,310.0 Cr | 2% | -1.7% | 15.9% | Stock Analytics | |
| DIVIS LABORATORIES | ₹245,426.0 Cr | 6.5% | 14.8% | 48.4% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹189,347.0 Cr | 1.2% | -2.5% | 37.2% | Stock Analytics | |
| CIPLA | ₹114,393.0 Cr | -0.3% | -3.9% | -11.4% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹97,240.2 Cr | -2.2% | 1.5% | -8.3% | Stock Analytics | |
NGL FINECHEM Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| NGL FINECHEM | -5.6% |
-18.9% |
99.8% |
| SENSEX | -0.5% |
-1.3% |
-5.4% |
You may also like the below Video Courses